Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS)

B.O. Khatri; J. Pelletier; L. Kappos; H.P. Hartung; G. Comi; F. Barkhof; P. von Rosenstiel; X. Meng; A. Grinspan; R. Hashmonay; J.A. Cohen

doi:https://doi.org/10.1016/j.msard.2013.11.006

Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS)

B.O. Khatri, J. Pelletier, L. Kappos, H.P. Hartung, G. Comi, F. Barkhof, P. von Rosenstiel, X. Meng, A. Grinspan, R. Hashmonay, J.A. Cohen

Radiology and Nuclear Medicine (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

12 Citations (Scopus)

Original language	English
Pages (from-to)	355-363
Journal	Multiple Sclerosis and Related Disorders
Volume	3
Issue number	3
DOIs	https://doi.org/10.1016/j.msard.2013.11.006
Publication status	Published - 2014

Access to Document

https://doi.org/10.1016/j.msard.2013.11.006

Cite this

Khatri, B. O., Pelletier, J., Kappos, L., Hartung, H. P., Comi, G., Barkhof, F., von Rosenstiel, P., Meng, X., Grinspan, A., Hashmonay, R., & Cohen, J. A. (2014). Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS). Multiple Sclerosis and Related Disorders, 3(3), 355-363. https://doi.org/10.1016/j.msard.2013.11.006

Khatri, B.O. ; Pelletier, J. ; Kappos, L. et al. / Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS). In: Multiple Sclerosis and Related Disorders. 2014 ; Vol. 3, No. 3. pp. 355-363.

@article{3e112b7e1be341549254fd653104f048,

title = "Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS)",

author = "B.O. Khatri and J. Pelletier and L. Kappos and H.P. Hartung and G. Comi and F. Barkhof and {von Rosenstiel}, P. and X. Meng and A. Grinspan and R. Hashmonay and J.A. Cohen",

year = "2014",

doi = "https://doi.org/10.1016/j.msard.2013.11.006",

language = "English",

volume = "3",

pages = "355--363",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

publisher = "Elsevier",

number = "3",

}

Khatri, BO, Pelletier, J, Kappos, L, Hartung, HP, Comi, G, Barkhof, F, von Rosenstiel, P, Meng, X, Grinspan, A, Hashmonay, R & Cohen, JA 2014, 'Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS)', Multiple Sclerosis and Related Disorders, vol. 3, no. 3, pp. 355-363. https://doi.org/10.1016/j.msard.2013.11.006

Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS). / Khatri, B.O.; Pelletier, J.; Kappos, L. et al.
In: Multiple Sclerosis and Related Disorders, Vol. 3, No. 3, 2014, p. 355-363.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS)

AU - Khatri, B.O.

AU - Pelletier, J.

AU - Kappos, L.

AU - Hartung, H.P.

AU - Comi, G.

AU - Barkhof, F.

AU - von Rosenstiel, P.

AU - Meng, X.

AU - Grinspan, A.

AU - Hashmonay, R.

AU - Cohen, J.A.

PY - 2014

Y1 - 2014

U2 - https://doi.org/10.1016/j.msard.2013.11.006

DO - https://doi.org/10.1016/j.msard.2013.11.006

M3 - Article

C2 - 25876473

SN - 2211-0348

VL - 3

SP - 355

EP - 363

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

IS - 3

ER -

Khatri BO, Pelletier J, Kappos L, Hartung HP, Comi G, Barkhof F et al. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS). Multiple Sclerosis and Related Disorders. 2014;3(3):355-363. doi: https://doi.org/10.1016/j.msard.2013.11.006